gtx-758
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2011 (NCT01326312)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Estrogen receptor alphaAGONIST
ESR1 agonist
Capesaris is proposed INN
Chemistry & pharmacology
Loading structure…
SMILES
O=C(c1ccc(O)c(F)c1)N(c1ccc(O)cc1)c1ccc(F)cc1- Mol. weight
- 341.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545017 ↗
Also known as
- 3-fluoro-n-(4-fluorophenyl)-4-hydroxy-n-(4-hydroxyphenyl)benzamide
- gtx-758
- gtx-758
- gtx-758
- gtx-758
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01615120 | Phase 2 | Jul 1, 2012 | GTx |
| NCT01420861 | Phase 2 | Sep 1, 2011 | GTx |
| NCT01393119 | Phase 2 | Aug 1, 2011 | GTx |
| NCT01326312 | Phase 2 | Jun 1, 2011 | GTx |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GTx | For profit | 4 | 4 | 1 | 2011 |
1 organizations
Page 1 / 1